News
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) Jul. 09, 2025 7:30 AM ET Altimmune, Inc. (ALT) ...
Altimmune, Inc. announced the enrollment of the first patient in its RESTORE Phase 2 trial, which is assessing the safety and efficacy of pemvidutide for treating Alcohol-Associated Liver Disease ...
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial. Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks.
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...
Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials. Click for my update of ALT stock.
US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive ...
Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.
Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results